Perfiles is the section of Pulso where a clinician’s career is the subject. Pedro Gonzalez’s career turns on a pattern he first noticed in somebody else’s recovery.
The training
Gonzalez trained in physical medicine and rehabilitation at NYU, a specialty built around a simple question: what does this person need in order to function again? Rehabilitation is measurement-driven and unglamorous about time. Progress is counted in transfers, gait speed, and stairs. “Rehab teaches you patience with physiology,” he says. “Tissue heals on its own schedule. Your job is to remove what is blocking it and then not get in the way.”
After residency he completed a fellowship in testosterone replacement therapy under Dr. Abraham Morgentaler, the Harvard urologist whose work reshaped how the field thinks about testosterone and prostate risk. The pairing of the two trainings, rehabilitation and hormones, looks unusual from the outside. From inside his practice, he says, it was one continuous observation.
The turn
“The patients who stalled were rarely stalling because the therapy plan was wrong,” he says. “They were stalling because they were not sleeping, their mood was flat, and in a significant number of men the testosterone was low and nobody had checked. We treated the shoulder. The system around the shoulder was the problem.”
That observation became a practice. He now works in Chicago in hormone optimization, functional medicine, and regenerative therapies, and is licensed in Illinois, Florida, Texas, and Puerto Rico. The rehabilitation habits came with him: baseline measurements before intervention, function as the outcome that counts, and a reluctance to credit a therapy for what time and training did.
On evidence
Gonzalez is at his most direct when the subject is his own field’s marketing. “Optimization is a word that should make clinicians suspicious,” he says. “If a man’s testosterone is in the normal range and he feels well, there is no deficiency to correct, and raising the number is not a therapy, it is a subscription.” His rule for his own patients is the guideline rule: symptoms, two low morning measurements, and a documented conversation about fertility suppression, red cell counts, and monitoring before anything is prescribed.
It is an unfashionable position in a market that rewards the opposite. He seems content with the trade. “The clinicians I want reading my work are the ones who check,” he says. “They are also the patients I want.”